{"id":98846,"date":"2019-11-20T16:44:06","date_gmt":"2019-11-21T00:44:06","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2019\/11\/encouraging-early-results-from-first-human-crispr-gene-therapy-trials"},"modified":"2019-11-20T16:44:06","modified_gmt":"2019-11-21T00:44:06","slug":"encouraging-early-results-from-first-human-crispr-gene-therapy-trials","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2019\/11\/encouraging-early-results-from-first-human-crispr-gene-therapy-trials","title":{"rendered":"Encouraging early results from first human CRISPR gene therapy trials"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/encouraging-early-results-from-first-human-crispr-gene-therapy-trials.jpg\"><\/a><\/p>\n<p>Promising preliminary data from one of the first human trials testing the safety and efficacy of a CRISPR gene therapy has just been revealed. Although it is too early to evaluate long-term effects, the initial reports are impressively successful for two patients with severe genetic blood diseases.<\/p>\n<p>Until February of this year, when pharmaceutical companies CRISPR Therapeutics and Vertex began a large global trial into a treatment called CTX001, no human <a class=\"\" href=\"https:\/\/newatlas.com\/crispr-gene-editing-first-human-trial\/46453\/\" data-cms-ai=\"0\">outside of China<\/a> had been officially treated with a CRISPR-based gene editing therapy.<\/p>\n<p>CTX001 was developed to treat two types of inherited blood disease, beta-thalassemia and sickle cell disease. Both conditions are caused by a mutation in a single gene and the treatment involves engineering a patient\u2019s stem cells with a single genetic change designed to raise levels of fetal hemoglobin in red blood cells.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Promising preliminary data from one of the first human trials testing the safety and efficacy of a CRISPR gene therapy has just been revealed. Although it is too early to evaluate long-term effects, the initial reports are impressively successful for two patients with severe genetic blood diseases. Until February of this year, when pharmaceutical companies [\u2026]<\/p>\n","protected":false},"author":396,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1902,11,412],"tags":[],"class_list":["post-98846","post","type-post","status-publish","format-standard","hentry","category-bioengineering","category-biotech-medical","category-genetics"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/98846","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/396"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=98846"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/98846\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=98846"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=98846"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=98846"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}